in ME/UCL UK Rituximab Clinical Trial
Welcome to the UK
rituximab trial Home page
Invest in ME is a UK charity campaigning for a strategy of biomedical research into Myalgic Encephalomyelitis (ME) and promoting better education about ME.
This website describes the UK rituximab
trial project which Invest in ME has initiated and has been organising since the international
researchers meeting and conference which the charity organised on 30/31 May 2013 and which was
announced on Invest in ME website on 6th June.
We are doing this to further advance biomedical research into ME and provide
hope for some to regain their lives, and for others to benefit from improved
knowledge about this disease.
at the research directions currently being pursued in ME/CFS, I am in no
doubt that the usage of rituximab is one of the most promising.”
Professor Jonathan Edwards
in ME are at the forefront of international biomedical research and have
by sheer determination and effort managed to put things in place for a
trial of rituximab to begin on ME patients in the UK.”
Malcolm Hooper & Margaret Williams
Read more in the paragraphs below or use the links in
the table to go directly to an area of interest.
At our 2011 Invest in ME international conference,
Norwegian cancer specialists Dr
Fluge and Professor Olav Mella announced strikingly successful results in their
pilot study of the immunotherapy drug Rituximab on ME/CFS patients. In that
67% of ME/CFS patients had moderate to major improvement, compared to only 13%
The pattern of response indicated that ME may have an
autoimmune component because rituximab works by temporarily wiping out
immune-system B cells, which are implicated in autoimmune disease.
groundbreaking results gained international attention when the study was
In Germany, Professor Carmen
Scheibenbogen is already looking at possibilities for a rituximab trial and in the US, Dr Andreas Kogelnik’s Open Medicine Institute is
raising funds for a study.
Dr Fluge and Professor
Mella are beginning a confirmatory trial in January 2014, part-funded by the
Norwegian government; at our 2013 conference, they presented further evidence of
the efficacy of rituximab in the treatment of ME patients.
Multiple confirmatory trials are
crucial because without evidence on safety and efficacy from independent studies
in several locations, regulatory bodies will not approve or license rituximab
for use in ME.
We believe that the UK needs a
rituximab trial, both to benefit UK patients and to support the international
effort. With your help, we can make this happen.
At the 2012 Invest
in ME international ME conference IiME announced we were looking into starting a rituximab trial in the UK. We have spent the last year working on that idea as
part of our efforts in setting up a Uk examination and research facility
for ME in Norwich.
On 6 June 2013, we announced
that we were initiating a UK rituximab trial and began fundraising for it.
Jonathan Edwards, Emeritus
Professor of Connective Tissue Medicine at University College London (UCL), has
agreed to advise us on all aspects of the trial. He is known worldwide for his
work in B cell immunology and as lead researcher in the clinical trials of
Rituximab for rheumatoid arthritis.
No UK expert is better placed than Professor Edwards to advise us on setting up
a rituximab trial for ME patients.
You can read his statement on the
The trial will take place at UCL,
led by Dr Jo Cambridge. It will be conducted by the same team that carried out
the rituximab research in rheumatoid arthritis and who have considerable
laboratory expertise in B cell immunology. This is the best possible team in the
UK to carry out the trial and we are confident that we can make this happen
All that remains to do is to
fund the trial so that it can start as soon as possible (see
Donate to Trial by clicking on the link to the
More detail about the trial is given in our
FAQs and News sections
using the buttons to the right.
We invite you to join us in this
Return to top of
Our proposal for an examination and research
facility for ME [R5] included a
national strategy of translational biomedical research. The
university is now preparing to begin the foundation project [R6].
The UK rituximab
trial fits into this strategy perfectly.
Please read our announcement
here) as well as the
news items to follow the progress of this project.
Invest in ME aim to build a fund to accomplish this
ourselves but we recognise this is a huge task and therefore are happy to accept support and donations from others who have the same objectives as
Invest in ME.
IiME are also discussing with our EMEA colleagues
on ways to increase biomedical research into ME.
We are confident these projects can be performed and started
Return to top of